Charles F. Eisenbeis

1.6k total citations
20 papers, 1.3k citations indexed

About

Charles F. Eisenbeis is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Charles F. Eisenbeis has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 10 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Charles F. Eisenbeis's work include Lymphoma Diagnosis and Treatment (9 papers), Viral-associated cancers and disorders (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Charles F. Eisenbeis is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Viral-associated cancers and disorders (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Charles F. Eisenbeis collaborates with scholars based in United States and Canada. Charles F. Eisenbeis's co-authors include U Storb, Harkanwal Preet Singh, Harinder Singh, Abraham L. Brass, Michael A. Caligiuri, Robert A. Baiocchi, Amy Banks, Pierluigi Porcu, Sameek Roychowdhury and Amy K. Ferketich and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Charles F. Eisenbeis

20 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles F. Eisenbeis United States	14	820	537	371	247	146	20	1.3k
Mark W. Brunvand United States	15	554 0.7×	293 0.5×	375 1.0×	176 0.7×	86 0.6×	22	1.2k
Chainarong Tunyaplin United States	12	864 1.1×	267 0.5×	406 1.1×	125 0.5×	94 0.6×	12	1.3k
Joan de Jong Netherlands	10	1.0k 1.2×	372 0.7×	494 1.3×	112 0.5×	203 1.4×	12	1.5k
Lorena Maestre Spain	15	744 0.9×	442 0.8×	325 0.9×	420 1.7×	158 1.1×	23	1.4k
Erich Piovan Italy	15	327 0.4×	305 0.6×	375 1.0×	147 0.6×	146 1.0×	33	915
Tina Goossens Germany	6	573 0.7×	368 0.7×	408 1.1×	523 2.1×	69 0.5×	7	1.2k
Ranjani Rajapaksa United States	17	1.3k 1.6×	807 1.5×	605 1.6×	175 0.7×	87 0.6×	23	1.9k
Sergio Roa United States	19	601 0.7×	226 0.4×	700 1.9×	322 1.3×	158 1.1×	35	1.3k
Liang‐Ji Zhou United States	9	781 1.0×	205 0.4×	320 0.9×	131 0.5×	151 1.0×	10	1.1k
Hong Ming Shen United States	14	791 1.0×	201 0.4×	537 1.4×	258 1.0×	78 0.5×	19	1.2k

Countries citing papers authored by Charles F. Eisenbeis

Since Specialization

Citations

This map shows the geographic impact of Charles F. Eisenbeis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles F. Eisenbeis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles F. Eisenbeis more than expected).

Fields of papers citing papers by Charles F. Eisenbeis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles F. Eisenbeis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles F. Eisenbeis. The network helps show where Charles F. Eisenbeis may publish in the future.

Co-authorship network of co-authors of Charles F. Eisenbeis

This figure shows the co-authorship network connecting the top 25 collaborators of Charles F. Eisenbeis. A scholar is included among the top collaborators of Charles F. Eisenbeis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles F. Eisenbeis. Charles F. Eisenbeis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Osborne, Cynthia, Charles F. Eisenbeis, Frankie A. Holmes, et al.. (2017). Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clinical Breast Cancer. 18(1). e89–e95. 7 indexed citations

2.

Khan, Khuda Dad, Christos Emmanouilides, Don M. Benson, et al.. (2006). A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. Clinical Cancer Research. 12(23). 7046–7053. 71 indexed citations

3.

Eisenbeis, Charles F., Gregory B. Lesinski, Mirela Anghelina, et al.. (2005). Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12. Journal of Clinical Oncology. 23(34). 8835–8844. 19 indexed citations

4.

Lin, T. S., Jeffrey S. Johnston, James T. Dalton, et al.. (2005). Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma.. Blood. 106(11). 2407–2407. 6 indexed citations

5.

Lin, Thomas S., Beth Fischer, Mollie E. Moran, et al.. (2005). Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.. Blood. 106(11). 944–944. 4 indexed citations

6.

Mone, Andrew P., Carolyn Cheney, Amy Banks, et al.. (2005). Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia. 20(2). 272–279. 91 indexed citations

7.

Mone, Andrew P., Shannon Puhalla, Susan P. Whitman, et al.. (2005). Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia. Blood. 106(10). 3380–3382. 35 indexed citations

8.

Eisenbeis, Charles F., John P. Leonard, Joseph D. Rosenblatt, et al.. (2004). Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients. Journal of Clinical Oncology. 22(14_suppl). 2534–2534. 1 indexed citations

9.

Roychowdhury, Sukla, Robert A. Baiocchi, Srinivas Vourganti, et al.. (2004). Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder. JNCI Journal of the National Cancer Institute. 96(19). 1447–1457. 26 indexed citations

10.

Eisenbeis, Charles F., Andrew J. Grainger, Beth Fischer, et al.. (2004). Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2. Clinical Cancer Research. 10(18). 6101–6110. 62 indexed citations

11.

Eisenbeis, Charles F., John P. Leonard, Joseph D. Rosenblatt, et al.. (2004). Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients. Journal of Clinical Oncology. 22(14_suppl). 2534–2534. 2 indexed citations

12.

Dierksheide, Julie, Robert A. Baiocchi, Amy K. Ferketich, et al.. (2004). IFN-γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood. 105(4). 1558–1565. 26 indexed citations

13.

Roychowdhury, Sameek, Robert A. Baiocchi, Darshna Bhatt, et al.. (2003). Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.. PubMed. 63(5). 965–71. 57 indexed citations

14.

Porcu, Pierluigi, Charles F. Eisenbeis, Ronald P. Pelletier, et al.. (2002). Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration. Blood. 100(7). 2341–2348. 41 indexed citations

15.

Baiocchi, Robert A., Charles F. Eisenbeis, Sameek Roychowdhury, et al.. (2001). GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. Journal of Clinical Investigation. 108(6). 887–894. 39 indexed citations

16.

Eisenbeis, Charles F., et al.. (2001). A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Annals of Hematology. 80(2). 121–123. 13 indexed citations

17.

Brass, Abraham L., et al.. (1996). Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1.. Genes & Development. 10(18). 2335–2347. 209 indexed citations

18.

Eisenbeis, Charles F., Harkanwal Preet Singh, & U Storb. (1995). Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.. Genes & Development. 9(11). 1377–1387. 399 indexed citations

19.

Eisenbeis, Charles F., Harinder Singh, & Ursula Storb. (1993). PU.1 is a Component of a Multiprotein Complex Which Binds an Essential Site in the Murine Immunoglobulin λ2-4 Enhancer. Molecular and Cellular Biology. 13(10). 6452–6461. 36 indexed citations

20.

Eisenbeis, Charles F., Harinder Singh, & U Storb. (1993). PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer.. Molecular and Cellular Biology. 13(10). 6452–6461. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact